Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Mar;57(3):308–312. doi: 10.1038/bjc.1988.68

Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine.

H Y al-Idrissi 1, E M Ibrahim 1, K A Abdullah 1, W A Ababtain 1, H A Boukhary 1, H M Macaulay 1
PMCID: PMC2246525  PMID: 3281702

Abstract

A double-blind, randomized, crossover study was conducted to compare the efficacy and safety of high-dose dexamethasone (Protocol D) with a combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD) in the management of chemotherapy-induced nausea and vomiting in cancer patients. All entered patients had received no prior chemotherapy. During the study chemotherapy was administered on an inpatient basis. The majority of patients (94%) were treated with cytotoxic drugs of significant emetogenic activity and 40% of the study group received cis-platin-containing combinations. Of the 60 evaluable patients, complete antinausea and antivomiting effects of D were observed in 30 (50%) and 34 (57%), respectively and of DMD in 17 (28%) and 26 patients (43%) respectively. The difference was not statistically significant (P = 0.09 and 0.24, respectively). Lack of significant difference between the two regimens was demonstrated irrespective of the administered cytotoxic drugs. The DMD protocol caused more adverse reactions than D. While 27 patients (45%) experienced no side effects from D, only 14 (24%) remained free of complications due to DMD (P = 0.001). Furthermore, DMD produced more sedation, insomnia, headache, diaphoresis, dizziness and diarrhoea than the D regimen. In addition it gave rise to more adverse effects on appetite and activity. Upon direct questioning, 37 patients (62%) expressed a preference for D, 14 (23%) preferred DMD and 9 (15%) found no difference between the two regimens. We conclude that, while the short DMD protocol has an antiemetic activity equivalent in its effectiveness to D, its associated adverse reactions would minimize its usefulness. Therefore, further investigations should be conducted to find a safer and more potent combination of antiemetics suitable for therapy in an outpatient setting.

Full text

PDF
308

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan S. G., Cornbleet M. A., Warrington P. S., Golland I. M., Leonard R. C., Smyth J. N. Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J (Clin Res Ed) 1984 Oct 6;289(6449):878–879. doi: 10.1136/bmj.289.6449.878-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blandford R. L., Dowdle J. R., Stephens M. R., Walker D. M. Sicca syndrome associated with idiopathic haemochromatosis. Br Med J. 1979 May 19;1(6174):1323–1323. doi: 10.1136/bmj.1.6174.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bruera E. D., Roca E., Cedaro L., Chacón R., Estévez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep. 1983 Apr;67(4):381–383. [PubMed] [Google Scholar]
  4. Cassileth P. A., Lusk E. J., Torri S., DiNubile N., Gerson S. L. Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med. 1983 Jul;143(7):1347–1349. [PubMed] [Google Scholar]
  5. Cassileth P. A., Lusk E. J., Torri S., Gerson S. L. Antiemetic efficacy of high-dose dexamethasone in induction therapy in acute nonlymphocytic leukemia. Ann Intern Med. 1984 May;100(5):701–702. doi: 10.7326/0003-4819-100-5-701. [DOI] [PubMed] [Google Scholar]
  6. Gralla R. J., Itri L. M., Pisko S. E., Squillante A. E., Kelsen D. P., Braun D. W., Jr, Bordin L. A., Braun T. J., Young C. W. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981 Oct 15;305(16):905–909. doi: 10.1056/NEJM198110153051601. [DOI] [PubMed] [Google Scholar]
  7. Ibrahim E. M., Al-Idrissi H. Y., Ibrahim A., Absood G., Al-Dossary E., Al-Jammaa A., Al-Ethan S., Eliopoulos A. Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol. 1986 Mar;22(3):283–288. doi: 10.1016/0277-5379(86)90392-5. [DOI] [PubMed] [Google Scholar]
  8. Krebs H. B., Myers M. B., Wheelock J. B., Goplerud D. R. Combination antiemetic therapy in cisplatin-induced nausea and vomiting. Cancer. 1985 Jun 1;55(11):2645–2648. doi: 10.1002/1097-0142(19850601)55:11<2645::aid-cncr2820551119>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  9. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Kelsen D. P., Reilly L. K., Groshen S., Bosl G. J., Kalman L. A. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer. 1985 Feb 1;55(3):527–534. doi: 10.1002/1097-0142(19850201)55:3<527::aid-cncr2820550310>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  10. Kris M. G., Tyson L. B., Gralla R. J., Clark R. A., Allen J. C., Reilly L. K. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med. 1983 Aug 18;309(7):433–434. doi: 10.1056/nejm198308183090718. [DOI] [PubMed] [Google Scholar]
  11. Kris M. G., Tyson L. B., Gralla R. J., Clark R. A., Allen J. C., Reilly L. K. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med. 1983 Aug 18;309(7):433–434. doi: 10.1056/nejm198308183090718. [DOI] [PubMed] [Google Scholar]
  12. Laszlo J., Lucas V. S., Jr Emesis as a critical problem in chemotherapy. N Engl J Med. 1981 Oct 15;305(16):948–949. doi: 10.1056/NEJM198110153051609. [DOI] [PubMed] [Google Scholar]
  13. Laszlo J. Nausea and vomiting as major complications of cancer chemotherapy. Drugs. 1983 Feb;25 (Suppl 1):1–7. doi: 10.2165/00003495-198300251-00002. [DOI] [PubMed] [Google Scholar]
  14. MOERTEL C. G., REITEMEIER R. J., GAGE R. P. A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS. JAMA. 1963 Oct 12;186:116–118. doi: 10.1001/jama.1963.03710020036011. [DOI] [PubMed] [Google Scholar]
  15. Markman M., Sheidler V., Ettinger D. S., Quaskey S. A., Mellits E. D. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med. 1984 Aug 30;311(9):549–552. doi: 10.1056/NEJM198408303110901. [DOI] [PubMed] [Google Scholar]
  16. Mason B. A., Dambra J., Grossman B., Catalano R. B. Effective control of cisplatin-induced nausea using high-dose steroids and droperidol. Cancer Treat Rep. 1982 Feb;66(2):243–245. [PubMed] [Google Scholar]
  17. Meyer B. R., Lewin M., Drayer D. E., Pasmantier M., Lonski L., Reidenberg M. M. Optimizing metoclopramide control of cisplatin-induced emesis. Ann Intern Med. 1984 Mar;100(3):393–395. doi: 10.7326/0003-4819-100-3-393. [DOI] [PubMed] [Google Scholar]
  18. Moertel C. G., Reitemeier R. J. Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology. 1969 Sep;57(3):262–268. [PubMed] [Google Scholar]
  19. Morran C., Smith D. C., Anderson D. A., McArdle C. S. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics. Br Med J. 1979 May 19;1(6174):1323–1324. doi: 10.1136/bmj.1.6174.1323-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Peroutka S. J., Snyder S. H. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982 Mar 20;1(8273):658–659. doi: 10.1016/s0140-6736(82)92206-1. [DOI] [PubMed] [Google Scholar]
  21. Sallan S. E., Cronin C., Zelen M., Zinberg N. E. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980 Jan 17;302(3):135–138. doi: 10.1056/NEJM198001173020302. [DOI] [PubMed] [Google Scholar]
  22. Seigel L. J., Longo D. L. The control of chemotherapy-induced emesis. Ann Intern Med. 1981 Sep;95(3):352–359. doi: 10.7326/0003-4819-95-3-352. [DOI] [PubMed] [Google Scholar]
  23. Strum S. B., McDermed J. E., Opfell R. W., Riech L. P. Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. JAMA. 1982 May 21;247(19):2683–2686. doi: 10.1001/jama.247.19.2683. [DOI] [PubMed] [Google Scholar]
  24. Strum S. B., McDermed J. E., Pileggi J., Riech L. P., Whitaker H. Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. A preliminary evaluation. Cancer. 1984 Mar 15;53(6):1432–1439. doi: 10.1002/1097-0142(19840315)53:6<1432::aid-cncr2820530636>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  25. Wampler G. The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis. Drugs. 1983 Feb;25 (Suppl 1):35–51. doi: 10.2165/00003495-198300251-00005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES